查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1654211

全身麻醉劑市場規模、佔有率、趨勢分析報告：按藥物、給藥途徑、最終用途、應用、地區、細分預測，2025-2030 年

General Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug (Propofol), By Route Of Administration (Intravenous), By End-use (Hospitals), By Application, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

全身麻醉劑市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，全球全身麻醉劑市場規模預計到2030年將達到65.6億美元，2025年至2030年期間的複合年成長率為3.68%。

這項預期成長是由幾個關鍵因素推動的，例如手術量的增加、麻醉技術的進步、慢性病盛行率的上升以及政府的支持措施。世界衛生組織 (WHO) 估計，由於醫療保健機會的改善以及選擇性手術和緊急手術的增加，手術數量正在增加。光是 2022 年，全球整體就會有約 2,000 萬例新發癌症病例和 970 萬例癌症相關死亡病例，突顯出外科手術介入的快速增加。外科手術的增加刺激了對全身麻醉的需求增加，這對於確保手術期間患者的安全和舒適至關重要。

政府擴大醫療保健和改善基礎設施的舉措進一步推動了市場成長。在北美和歐洲等許多地區，醫療改革和資金投入提高了外科服務的可用性和品質。例如，美國《平價醫療法案》的實施以及其他國家的類似努力正在擴大手術的機會並增加對全身麻醉劑的需求。對醫療保健基礎設施和新醫療設施的投資將會增強麻醉市場。

麻醉技術的進步在市場成長中發揮著至關重要的作用。標靶輸注系統、安全性較高的新型麻醉劑、以及增強的監測技術等技術創新提高了麻醉的效率和有效性。例如，開發麻醉起效和恢復時間更快的麻醉劑將改善患者的治療效果並推動需求。

全身麻醉劑市場報告重點

  • 到 2024 年，Propofol預計將佔據市場主導地位，佔有 25.52% 的佔有率，並在預測期內以最快的複合年成長率成長。Propofol具有起效快、恢復快的特點，可提高病患的舒適度和手術效率。
  • 預計靜脈注射部分將在 2024 年佔據最大的收益佔有率，並且預計在預測期內以 3.9% 的最快複合年成長率成長。
  • 2024 年，膝關節關節重建和髖置換術領域將佔據市場主導地位，佔據相當大的收益佔有率。這項優勢是由骨關節炎盛行率的上升、手術技術的進步和人口趨勢所推動的。
  • 2024 年，醫院部門將佔據市場主導地位，佔據 67.05% 的顯著收益佔有率。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章全身麻醉劑市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 全身麻醉劑市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析

第 4 章 全身麻醉劑市場：藥物估計與趨勢分析

  • 全球全身麻醉劑市場：藥物儀表板
  • 全球全身麻醉劑市場：藥物變異分析
  • 全球全身麻醉劑市場：藥物變異分析
  • SEVOFLURANE
  • Propofol
  • Dexmedetomidine
  • REMIFENTANIL
  • DESFLURANE
  • 咪達唑侖
  • 其他

第 5 章 全身麻醉劑市場：按給藥途徑分類的估計和趨勢

  • 全球全身麻醉劑市場：給藥途徑儀表板
  • 全球全身麻醉劑市場：給藥途徑變化分析
  • 按給藥途徑分類的收益
  • 靜脈
  • 吸入

第6章 全身麻醉劑市場：依最終用途的估計與趨勢分析

  • 全球全身麻醉劑市場：最終用途儀表板
  • 全球全身麻醉劑市場：最終用途變化分析
  • 按最終用途分類的收益
  • 醫院
  • 門診手術中心
  • 其他

第 7 章 全身麻醉劑市場：按應用進行的估計和趨勢分析

  • 全球全身麻醉劑市場：應用儀表板
  • 全球全身麻醉劑市場：應用趨勢分析
  • 按用途分類的收益
  • 心血管手術
  • 癌症
  • 一般外科
  • 關節重建和髖關節置換術
  • 其他

8. 全身麻醉劑市場：依藥物、給藥途徑、最終用途和應用區域進行的估計和趨勢分析

  • 區域控制面板
  • 市場規模、預測趨勢分析，2018-2030
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商及通路夥伴名單
    • 2024 年主要企業的市場佔有率分析
    • Baxter International Inc.
    • AstraZeneca
    • AbbVie Inc.
    • B. Braun Melsungen AG
    • Fresenius SE &Co. KgaA
    • Pfizer
    • Hospira Inc.
    • Aspen Pharmacare Holdings Limited
    • Hikama Pharmaceuticals plc
    • Abbott Laboratories
Product Code: GVR-4-68040-455-1

General Anesthesia Drugs Market Growth & Trends:

The global general anesthesia drugs market size is projected to reach USD 6.56 billion by 2030, and projected to grow at a CAGR of 3.68% from 2025 to 2030, according to a new report by Grand View Research, Inc. This projected growth is driven by several critical factors, including increasing surgical volumes, advancements in anesthesia technology, rising prevalence of chronic diseases, and supportive government initiatives. The World Health Organization (WHO) estimates that the volume of surgeries is increasing due to greater access to healthcare and the growing number of elective and emergency procedures. In 2022 alone, there were nearly 20 million new cancer cases and 9.7 million cancer-related deaths globally, highlighting the surge in surgical interventions required. This increase in surgical activity is fueling a heightened demand for general anesthesia, as it is crucial for ensuring patient safety and comfort during operations.

Government initiatives to expand healthcare access and improve infrastructure further support market growth. In many regions, including North America and Europe, healthcare reforms and funding are increasing the availability of surgical services and improving the quality of care. For instance, the U.S. Affordable Care Act and similar initiatives in other countries are expanding surgery access, contributing to the higher demand for general anesthesia drugs. Investments in healthcare infrastructure and new healthcare facilities enhance the anesthesia market.

Technological advancements in anesthesia play a significant role in market growth. Innovations such as target-controlled infusion systems, new anesthetic agents with improved safety profiles, and enhanced monitoring technologies contribute to the efficiency and effectiveness of anesthesia. For instance, developing anesthetics with faster onset and recovery times improves patient outcomes and drives demand.

General Anesthesia Drugs Market Report Highlights:

  • In 2024, the propofol segment dominated the market with a substantial share of 25.52% and is also expected to grow at the fastest CAGR during the forecast period. Propofol is renowned for its rapid onset and quick recovery times, which enhance patient comfort and procedural efficiency.
  • The intravenous (IV) segment held the largest revenue share in 2024 and is also expected to grow at the fastest CAGR of 3.9% during the forecast period.
  • In 2024, the knee and hip replacements segment dominated the market, capturing a substantial revenue share. This dominance is driven by the increasing prevalence of osteoarthritis, advancements in surgical techniques, and demographic trends.
  • In 2024, the hospitals segment dominated the market, capturing a substantial revenue share of 67.05%.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Route of Administration
    • 1.2.3. End Use
    • 1.2.4. Application
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Outlook
    • 2.2.2. Route of Administration
    • 2.2.3. End Use
    • 2.2.4. Application
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. General Anesthesia Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Volume of Surgical Procedures
      • 3.2.1.2. Advancements In Anesthesia Technology
      • 3.2.1.3. Regulatory Developments
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Regulatory and Compliance Challenges
      • 3.2.2.2. Adverse Effects and Safety Concerns
  • 3.3. General Anesthesia Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. General Anesthesia Drugs Market: Drug Estimates & Trend Analysis

  • 4.1. Global General Anesthesia Drugs Market: Drug Dashboard
  • 4.2. Global General Anesthesia Drugs Market: Drug Movement Analysis
  • 4.3. Global General Anesthesia Drugs Market by Drug, Revenue
  • 4.4. Sevoflurane
    • 4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Propofol
    • 4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Dexmedetomidine
    • 4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Remifentanil
    • 4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Desflurane
    • 4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Midazolam
    • 4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. General Anesthesia Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global General Anesthesia Drugs Market: Route of Administration Dashboard
  • 5.2. Global General Anesthesia Drugs Market: Route of Administration Movement Analysis
  • 5.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 5.4. Intravenous
    • 5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Inhaled
    • 5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. General Anesthesia Drugs Market: End Use Estimates & Trend Analysis

  • 6.1. Global General Anesthesia Drugs Market: End Use Dashboard
  • 6.2. Global General Anesthesia Drugs Market: End Use Movement Analysis
  • 6.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Ambulatory Surgical Centers
    • 6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. General Anesthesia Drugs Market: Application Estimates & Trend Analysis

  • 7.1. Global General Anesthesia Drugs Market: Application Dashboard
  • 7.2. Global General Anesthesia Drugs Market: Application Movement Analysis
  • 7.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
  • 7.4. Heart Surgeries
    • 7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Cancer
    • 7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. General Surgery
    • 7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Knee and hip replacements
    • 7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Other
    • 7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. General Anesthesia Drugs Market: Regional Estimates & Trend Analysis by Drug, Route of Administration, End Use and Application

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Vendor Landscape
    • 9.2.1. List of key distributors and channel partners
    • 9.2.2. Key company market share analysis, 2024
    • 9.2.3. Baxter International Inc.
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Drug benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. AstraZeneca
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Drug benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. AbbVie Inc.
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Drug benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. B. Braun Melsungen AG
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Drug benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. Fresenius SE & Co. KgaA
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Drug benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Pfizer
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Drug benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Hospira Inc.
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Drug benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Aspen Pharmacare Holdings Limited
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Drug benchmarking
      • 9.2.10.4. Strategic initiatives
    • 9.2.11. Hikama Pharmaceuticals plc
      • 9.2.11.1. Company overview
      • 9.2.11.2. Financial performance
      • 9.2.11.3. Drug benchmarking
      • 9.2.11.4. Strategic initiatives
    • 9.2.12. Abbott Laboratories
      • 9.2.12.1. Company overview
      • 9.2.12.2. Financial performance
      • 9.2.12.3. Drug benchmarking
      • 9.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List Of Abbreviation
  • Table 2 North America General Anesthesia Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 3 North America General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 4 North America General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 5 North America General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 6 North America General Anesthesia Drugs Market, Application, 2018 - 2030 (USD Million)
  • Table 7 U.S. General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 8 U.S. General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 9 U.S. General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 10 U.S. General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 11 Canada General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 12 Canada General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Canada General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 14 Canada General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 15 Mexico General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 16 Mexico General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 17 Mexico General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18 Mexico General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 19 Europe General Anesthesia Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 20 Europe General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 21 Europe General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Europe General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 23 Europe General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 24 Germany General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 25 Germany General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 Germany General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 27 Germany General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 28 UK General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 29 UK General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 UK General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 31 UK General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 32 France General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 33 France General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 France General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 35 France General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 36 Italy General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 37 Italy General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 Italy General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 39 Italy General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 40 Spain General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 41 Spain General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Spain General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43 Spain General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 44 Denmark General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 45 Denmark General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Denmark General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 47 Denmark General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 48 Sweden General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 49 Sweden General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Sweden General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 51 Sweden General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 52 Norway General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 53 Norway General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 Norway General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 55 Norway General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific General Anesthesia Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 61 China General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 62 China General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 China General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 64 China General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 65 Japan General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 66 Japan General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Japan General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 68 Japan General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 69 India General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 70 India General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 India General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 72 India General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 73 South Korea General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 74 South Korea General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 South Korea General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 76 South Korea General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 77 Australia General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 78 Australia General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 79 Australia General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 80 Australia General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 81 Thailand General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 82 Thailand General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 Thailand General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 84 Thailand General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 85 Latin America General Anesthesia Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 86 Latin America General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 87 Latin America General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 88 Latin America General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 89 Latin America General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 90 Brazil General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 91 Brazil General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 Brazil General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 93 Brazil General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 94 Argentina General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 95 Argentina General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 96 Argentina General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 97 Argentina General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 98 MEA General Anesthesia Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 99 MEA General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 100 MEA General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 101 MEA General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 102 MEA General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 103 South Africa General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 104 South Africa General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 105 South Africa General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 106 South Africa General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 111 UAE General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 112 UAE General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 113 UAE General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 114 UAE General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 115 Kuwait General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 116 Kuwait General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 117 Kuwait General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 118 Kuwait General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 General Anesthesia Drugs Market: Market Outlook
  • Fig. 14 Colorectal Surgery Competitive Insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 General Anesthesia Drugs Market Driver Impact
  • Fig. 18 General Anesthesia Drugs Market Restraint Impact
  • Fig. 19 General Anesthesia Drugs Market Strategic Initiatives Analysis
  • Fig. 20 General Anesthesia Drugs Market: Drug Movement Analysis
  • Fig. 21 General Anesthesia Drugs Market: Drug Outlook and Key Takeaways
  • Fig. 22 Sevoflurane market estimates and forecast, 2018 - 2030
  • Fig. 23 Propofol market estimates and forecast, 2018 - 2030
  • Fig. 24 Dexmedetomidine market estimates and forecast, 2018 - 2030
  • Fig. 25 Remifentanil market estimates and forecast, 2018 - 2030
  • Fig. 26 Desflurane market estimates and forecast, 2018 - 2030
  • Fig. 27 Midazolam market estimates and forecast, 2018 - 2030
  • Fig. 28 Others market estimates and forecast, 2018 - 2030
  • Fig. 29 General Anesthesia Drugs Market: Route of Administration Movement Analysis
  • Fig. 30 General Anesthesia Drugs Market: Route of Administration Outlook and Key Takeaways
  • Fig. 31 Intravenous market estimates and forecast, 2018 - 2030
  • Fig. 32 Inhaled market estimates and forecast, 2018 - 2030
  • Fig. 33 General Anesthesia Drugs Market: End Use Movement Analysis
  • Fig. 34 General Anesthesia Drugs Market: End Use Outlook and Key Takeaways
  • Fig. 35 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 36 Ambulatory Surgical Centers market estimates and forecast, 2018 - 2030
  • Fig. 37 Others market estimates and forecast, 2018 - 2030
  • Fig. 38 General Anesthesia Drugs Market: Application Movement Analysis
  • Fig. 39 General Anesthesia Drugs Market: Application Outlook and Key Takeaways
  • Fig. 40 Heart Surgeries market estimates and forecast, 2018 - 2030
  • Fig. 41 Cancer market estimates and forecast, 2018 - 2030
  • Fig. 42 General Surgery market estimates and forecast, 2018 - 2030
  • Fig. 43 Knee and hip replacements market estimates and forecast, 2018 - 2030
  • Fig. 44 Other market estimates and forecast, 2018 - 2030
  • Fig. 45 Global General Anesthesia Drugs Market: Regional Movement Analysis
  • Fig. 46 Global General Anesthesia Drugs Market: Regional Outlook and Key Takeaways
  • Fig. 47 Global General Anesthesia Drugs Market share and leading players
  • Fig. 48 North America, by country
  • Fig. 49 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 U.S. key country dynamics
  • Fig. 51 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Canada key country dynamics
  • Fig. 53 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico key country dynamics
  • Fig. 55 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 UK key country dynamics
  • Fig. 58 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Germany key country dynamics
  • Fig. 60 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 France key country dynamics
  • Fig. 62 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Italy key country dynamics
  • Fig. 64 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Spain key country dynamics
  • Fig. 66 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Denmark key country dynamics
  • Fig. 68 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Sweden key country dynamics
  • Fig. 70 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Norway key country dynamics
  • Fig. 72 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 China key country dynamics
  • Fig. 75 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Japan key country dynamics
  • Fig. 77 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 India key country dynamics
  • Fig. 79 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Thailand key country dynamics
  • Fig. 81 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 South Korea key country dynamics
  • Fig. 83 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Australia key country dynamics
  • Fig. 85 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Brazil key country dynamics
  • Fig. 88 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Argentina key country dynamics
  • Fig. 90 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 South Africa key country dynamics
  • Fig. 93 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Saudi Arabia key country dynamics
  • Fig. 95 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 UAE key country dynamics
  • Fig. 97 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Kuwait key country dynamics
  • Fig. 99 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Market share of key market players- General Anesthesia Drugs Market